# ARAKODA® (tafenoquine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tafenoquine

> The FDA approved ARAKODA® (tafenoquine), sponsored by GSK plc (GSK), on July 20, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ARAKODA® (tafenoquine) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Chronic Babesiosis](https://sec-api.dev/indications/chronic-babesiosis), [Babesiosis](https://sec-api.dev/indications/babesiosis), [Malaria, Vivax](https://sec-api.dev/indications/malaria-vivax) |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### July 20, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210795 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180720, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product KRINTAFEL (TAFENOQUINE SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210795%22

### October 1, 2026: interim data readout

- Status: scheduled. Date confidence: exact.
- First seen 2026-09-14, last confirmed 2026-09-14.
- SEC Form 8-K (accession 0001213900-26-099702): "Enrollment required for the prespecified interim analysis is complete, and the Data Safety Monitoring Board ("DSMB") analysis is scheduled for October 1, 2026." https://www.sec.gov/Archives/edgar/data/1946563/000121390026099702/ea0305442-8k_60degree.htm

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Babesiosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06656351 (B-FREE Chronic Babesiosis Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor 60 Degrees Pharmaceuticals LLC." https://clinicaltrials.gov/study/NCT06656351

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Babesiosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06656351 (B-FREE Chronic Babesiosis Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor 60 Degrees Pharmaceuticals LLC." https://clinicaltrials.gov/study/NCT06656351

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Babesiosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06207370 (Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor 60 Degrees Pharmaceuticals LLC." https://clinicaltrials.gov/study/NCT06207370

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Babesiosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06207370 (Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor 60 Degrees Pharmaceuticals LLC." https://clinicaltrials.gov/study/NCT06207370

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Malaria, Vivax.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06666491 (An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06666491

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Malaria, Vivax.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06666491 (An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06666491

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [March 2027](https://sec-api.dev/fda-calendar/2027-03), [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tafenoquine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARAKODA® (tafenoquine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tafenoquine

```bibtex
@misc{secapidev_pdufa_tafenoquine_20261116,
  title        = {ARAKODA® (tafenoquine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tafenoquine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tafenoquine_20261116","title":"ARAKODA® (tafenoquine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tafenoquine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
